Literature DB >> 9450914

Stereodependent inhibition of plasminogen activator inhibitor type 1 by phosphorothioate oligonucleotides: proof of sequence specificity in cell culture and in vivo rat experiments.

W J Stec1, C S Cierniewski, A Okruszek, A Kobylańska, Z Pawłowska, M Koziołkiewicz, E Pluskota, A Maciaszek, B Rebowska, M Stasiak.   

Abstract

Hexadecadeoxyribonucleotides complementary to a fragment of human PAI-1 mRNA located upstream of the start codon and their phosphorothioate analogs were studied in cultured HUVECs as sequence-dependent inhibitors of PAI-1 expression. The activity of the random mixture of diastereomers of phosphorothioate hexadecanucleotide PS-16H has been compared with that of isosequential, stereoregular [All-Sp] and [All-Rp] isomers. The highest inhibitory effect on PAI-1 synthesis was observed with the [All-Sp] diastereomer. Stereorandom phosphorothioate oligonucleotide PS-16R complementary to the same region of rat PAI-1 mRNA, when injected into tail vein of rats, substantially decreased the level of PAI-1 in blood plasma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9450914     DOI: 10.1089/oli.1.1997.7.567

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  5 in total

1.  Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages.

Authors:  W Brad Wan; Michael T Migawa; Guillermo Vasquez; Heather M Murray; Josh G Nichols; Hans Gaus; Andres Berdeja; Sam Lee; Christopher E Hart; Walt F Lima; Eric E Swayze; Punit P Seth
Journal:  Nucleic Acids Res       Date:  2014-11-14       Impact factor: 16.971

Review 2.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

3.  Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides.

Authors:  Naoki Iwamoto; David C D Butler; Nenad Svrzikapa; Susovan Mohapatra; Ivan Zlatev; Dinah W Y Sah; Stephany M Standley; Genliang Lu; Luciano H Apponi; Maria Frank-Kamenetsky; Jason Jingxin Zhang; Chandra Vargeese; Gregory L Verdine
Journal:  Nat Biotechnol       Date:  2017-08-21       Impact factor: 54.908

4.  Inhomogeneous Diastereomeric Composition of Mongersen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment.

Authors:  Lorenzo Arrico; Carmine Stolfi; Irene Marafini; Giovanni Monteleone; Salvatore Demartis; Salvatore Bellinvia; Francesca Viti; Marie McNulty; Irene Cabani; Anita Falezza; Lorenzo Di Bari
Journal:  Nucleic Acid Ther       Date:  2022-03-09       Impact factor: 4.244

Review 5.  Targeting RNA: A Transformative Therapeutic Strategy.

Authors:  Wei Yin; Mark Rogge
Journal:  Clin Transl Sci       Date:  2019-02-27       Impact factor: 4.689

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.